Open Access Articles- Top Results for Tigatuzumab


Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Clinical data
918127-53-4 7pxN
Chemical data
Formula C6406H9924N1716O2012S46
144.6 kDa
 14pxN (what is this?)  (verify)

Tigatuzumab (CS-1008) is a monoclonal antibody[1] for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed,[2] Phase II trials for colorectal cancer[3] and non-small cell lung cancer[4] are running, and a study for ovarian cancer has been approved.[5]

The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.[6]

A recent study reports on the preclinical validation of 111In-labeled anti-DR5 humanised antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in cancer patients, and establish dose ranges for receptor saturation kinetics in vivo.[7]


  1. ^ WHO Drug Information
  2. ^ NCI: Combination Therapy Targets Pancreatic Cancer Stem Cells
  3. ^ NCI: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
  4. ^ NCI: CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
  5. ^ NCI: Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
  6. ^ NCI: CS-1008
  7. ^

Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.